datetime,headline,summary,related,lang,source
2020-11-27 01:11:14-05:00,Russia agrees to produce Sputnik V in India,"MOSCOW: Russia's sovereign wealth fund and Indian pharmaceutical company Hetero have agreed to produce over 100 million doses per year in India of the Sputnik V vaccine against COVID-19, according to a statement on the Sputnik V Twitter account on Friday.Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021, the statement said.Phase II-III trials are ongoing in India, the statement said. Drugmaker Dr Reddy's Laboratories Ltd has said it expects late-stage trials to be completed by as early as March 2021.",RDY,en,Economic Times India
2020-11-23 00:00:00-05:00,Sensex pares gains after hitting record highs in opening trade; RIL rises,"In the 50-share pack Nifty, IndusInd Bank was the biggest gainer, up 3.87 per cent. Divis Lab, Bajaj Finserv, NTPC, Bajaj Finance, Reliance Industries and Dr Reddys Labs were among other gainers.",RDY,en,Economic Times India
2020-11-18 23:59:24-05:00,Dr Reddy's starts detailed investigation into anonymous complaint,"New Delhi: Drug major Dr Reddy's Laboratories on Thursday said it has commenced a detailed investigation into an anonymous complaint regarding healthcare professionals in Ukraine and potentially in other countries being provided with improper benefits. The company has a wholly-owned subsidiary and a global office in Ukraine. ""Dr Reddy's Laboratories has commenced a detailed investigation into an anonymous complaint. The complaint alleges that healthcare professionals in Ukraine and potentially in other countries were provided with improper benefits in violation of US laws,"" the company said in a regulatory filing. The investigation is being carried out by a reputed independent US law firm, Dr Reddy's Laboratories said without providing details. Shares of Dr Reddy's Laboratories were trading 1.13 per cent higher at Rs 4,756.35 apiece on BSE.",RDY,en,Economic Times India
2020-11-12 21:38:00-05:00,"Adani Green Energy, Laurus Labs, among top value creators in Samvat 2076","Meanwhile, Dr Reddy's Laboratories, Cipla, Infosys, HCL Technologies were up between 25 per cent and 75 per cent.",RDY,en,Business Standard
2020-11-09 01:11:42-05:00,"Mouth Ulcers Treatment Market Will See Strong Expansion through 2020-2025 | Top Key Company’s –3M, GSK, Blistex, Pfizer, Sunstar, Bristol-Myers Squibb, Sannova, Dr Reddys",A market study ”Global Mouth Ulcers Treatment Market” examines the performance of the Global Mouth Ulcers Treatment Market 2020. It encloses an in-depth Research of the Mouth Ulcers Treatment Market state and the competitive landscape globally. This report analyzes the,RDY,en,OpenPR
2020-10-29 03:35:39-05:00,Dr Reddy's partners with Department of Biotechnology for Sputnik V vaccine clinical trials in India,"HYDERABAD: Dr Reddy's Laboratories Ltd on Thursday announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), for advisory support on clinical trials of Sputnik V vaccine in India.According to a press release from the city-based drug maker, the partnership will allow Dr Reddy's to identify and use some of BIRAC's clinical trial centres for the vaccine, which are funded under the National Biopharma Mission (NBM), implemented by Project Management Unit-NBM at BIRAC.Further, the company will have access to Good Clinical Laboratory Practice (GCLP) labs to conduct immunogenicity assay testing of the vaccine.Immunogenecity refers to the ability of an antigen to induce an immune response.Chairman of Dr Reddys Laboratories, Satish Reddy said, ""We are pleased with the collaboration with BIRAC as an advisory partner for clinical trials of the Sputnik V vaccine in India. We look forward to working with them to accelerate our efforts in bringing the vaccine to India.",RDY,en,Economic Times India
2020-10-29 03:35:00-05:00,Dr Reddy's partners with Department of Biotechnology for Sputnik V vaccine clinical trials in India,"Chairman of Dr Reddys Laboratories, Satish Reddy said, ""We are pleased with the collaboration with BIRAC as an advisory partner for clinical trials of the Sputnik V vaccine in India. We look forward to working with them to accelerate our efforts in bringing the vaccine to India.""",RDY,en,Economic Times India
2020-10-29 02:37:34-05:00,Dr Reddy's partners with Dept of Biotechnology for Sputnik V vaccine clinical trials in India | Health,"Dr Reddy's Laboratories Ltd on Thursday announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), for advisory support on clinical trials of Sputnik V vaccine in India.",RDY,en,Devdiscourse
2020-10-28 08:05:54-05:00,India trials of Russian Sputnik-V vaccine may end as early as March: Dr Reddy's,"Drugmaker Dr Reddy's Laboratories Ltd on Wednesday rolled out a preliminary timeline for the India trials of Russia's coronavirus vaccine candidate, with the late-stage expected to be completed by as early as March 2021.",RDY,en,Reuters India
2020-10-28 05:38:00-05:00,"Dr Reddy's Q2 PAT down 30% to Rs 762 crore from Rs 1,092 cr year-ago","The PAT of Dr Reddys Laboratories for the quarter ended on September 30, 2020, was down by 30 per cent at Rs 762.3 crore compared to Rs 1,092.5 crore during the corresponding quarter last fiscal",RDY,en,Business Standard
2020-10-28 04:11:00-05:00,Dr Reddy's Laboratories Q2 results: Net profit falls 30% to Rs 762 crore; revenue up 2%,"Dr Reddy's Laboratories (DRL) on Wednesday posted a 30 per cent rise in net profit to Rs 762.3 crore in the second quarter of FY21 as against Rs 1,092.5 crore in the corresponding period of last year",RDY,en,Business Today
2020-10-22 11:10:18.320000-05:00,Dr Reddys CIO assures of safe operations after cyber-attack,"Mumbai: A huge data-breach has affected the functioning of pharmaceutical major - Dr Reddys Laboratories. At 11:44 AM on Thursday, exchange houses were intimated about an outage. By then, the Hyderabad headquartered pharmaceutical firm had already shut down its data services. Reports are yet awaited on the extent of the data breach . However, it has resulted in a shut down in plants across the world. Dr Reddys operates plants at Brazil, United Kingdom, Russia and United States besides India. With the data services shut down, the website is also down. In a filing report, Mukesh Rathi, CIO for Dr Reddy's Laboratories is quoted as saying, ""We are anticipating all services to be up within 24 hours and we do not foresee any major impact on our operations due to this incident."" After the filing, stocks of Dr Reddy's Labs tanked by 3 percent but recovered to close the day at a decline of Rs 23.30 per share to quote Rs 5,023.60. The Data breach gains significance considering Dr Reddy's had recently received approval for clinical trail of Sputnik vaccine for Covid 19 in India.",RDY,en,Sify.com
2020-10-22 03:59:00-05:00,Dr Reddy's shares fell over 3% — the drug maker isolated all data service centers after a cyber attack,"One of Indias largest pharma companies, Dr Reddys Laboratories has been hit by a cyber-attack and has isolated its data services. Dr Reddy's said in a statement,",RDY,en,Business Insider India
2020-10-22 01:33:40-05:00,Dr Reddy's to shut key plants after data breach,"A data breach at Dr Reddy's Laboratories Ltd prompted the Indian drugmaker to shut its key plants globally, television channel ET Now reported on Thursday, citing sources. Shares of the company, which has a partnership to run clinical trials of Russia's Sputnik-V Covid-19 vaccine in India, fell as much as 4.3 per cent on the news, dragging the Nifty pharma sub-index down two",RDY,en,Deccan Herald
2020-10-17 23:09:58-05:00,Russia's coronavirus vaccine Sputnik V gets nod for late-stage trials in India,"The Russian Direct Investment Fund (RDIF) and Dr Reddy's Laboratories Ltd have received renewed approval to conduct late-stage clinical trials in India of the Russian COVID-19 vaccine, the sovereign wealth fund said.",RDY,en,IBTimes India
2020-10-17 05:08:33-05:00,Russia receives renewed approval for COVID-19 vaccine trials in India: RDIF,"The Russian Direct Investment Fund (RDIF) and Dr Reddy's Laboratories Ltd have received renewed approval to conduct late-stage clinical trials in India of the Russian COVID-19 vaccine, the sovereign wealth fund said on Saturday.",RDY,en,Reuters India
2020-10-13 08:27:44-05:00,"Glycosylated Hemoglobin C-peptide Market to grow with electrifying over Forecast Period 2020-2028| Prominent Players - Medtronic, Dr.Reddy's Laboratories, Roche, Biocon, Sanofi, Celltrion, Sandoz International","Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Glycosylated Hemoglobin C-peptide Market which would mention How the Covid-19 is affecting the Glycosylated Hemoglobin C-peptide Industry, Market Trends and Potential Opportunities",RDY,en,OpenPR
2020-10-07 10:28:30-05:00,"Capecitabine Fumarate Market 2020: Soaring Demand Assures Motivated Revenue Share by 2025 | Analysis by Novartis, Sun Pharma, Pfizer, Dr Reddys, Mylan, Akorn, Emcure Pharms",Global Capecitabine Fumarate Market Synopsis: The exclusive research report on the Global Capecitabine Fumarate Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global Capecitabine Fumarate Industry research,RDY,en,OpenPR
2020-10-06 21:31:00-05:00,"Coronavirus LIVE: Cases surge in India with over 69,0000 new infections","Coronavirus update: DCGI expert panel has directed the pharma giant Dr Reddy's Laboratories (DRL) to submit a revised protocol for performing phase 2,3 clinical trials of the Russian COVID-19 vaccine",RDY,en,Business Standard
2020-10-05 06:14:00-05:00,Dr Reddy's says it aims to cut greenhouse gas emissions by 55% by 2030,"Dr Reddy's Laboratories on Monday said it has committed to reduce its greenhouse gas emissions by 55 per cent by 2030. The Hyderabad-based drug major has joined hands with the Science Based Targets initiative (SBTi), thus becoming the first Indian and the third Asian pharmaceutical company to have set its science-based targets to further minimise environmental impact, Dr Reddy's Laboratories said in a statement. The company has committed to reducing its Scope 1 and 2 greenhouse gas (GHG) emissions by 55 per cent by 2030 from 2017-18 base year, which are in line with the latest climate science of limiting global warming to below 1.5C above pre-industrial levels, it added. ""Continuous improvement in our environmental performance is a notable aspect of our sustainability journey. We are delighted to join SBTi in taking a science-based approach to set our GHG emission reduction targets and accelerating our efforts to creating a positive impact on our planet,"" Dr Reddy's Laboratories …",RDY,en,Business Standard
2020-10-05 05:44:30-05:00,"Dr Reddy's joins hands with SBTi, aims to cut greenhouse gas emissions by 55 per cent by 2030","Dr Reddy's Laboratories on Monday said it has committed to reduce its greenhouse gas emissions by 55 per cent by 2030. The Hyderabad-based drug major has joined hands with the Science Based Targets initiative (SBTi), thus becoming the first Indian and the third Asian pharmaceutical company to have set its science-based targets to further minimise environmental impact, Dr Reddy's Laboratories said in a statement. The company has committed to reducing its Scope 1 and 2 greenhouse gas (GHG) emissions by 55 per cent by 2030 from 2017-18 base year, which are in line with the latest climate science of limiting global warming to below 1.5°C above pre-industrial levels, it added. ""Continuous improvement in our environmental performance is a notable aspect of our sustainability journey. We are delighted to join SBTi in taking a science-based approach to set our GHG emission reduction targets and accelerating our efforts to creating a positive impact on our planet,"" Dr Reddy's Laboratories Co-chairman and Managing Director G V Prasad said.",RDY,en,Economic Times India
2020-09-27 20:46:00-05:00,"Stocks in the news: RIL, Vodafone Idea, Dr Reddy’s Labs, Mindtree and Sun Pharma","Dr Reddy's Laboratories on Saturday said it has launched Dimethyl Fumarate delayed-release capsules, used to treat multiple sclerosis (MS), in the US market.",RDY,en,Economic Times India
2020-09-20 23:29:10-05:00,"Over 60K sign up for Russian Covid vax, 700 injected","Moscow, Sep 21 (IANS) More than 60,000 people have applied to volunteer for the coronavirus vaccine trials in Moscow and over 700 people have been injected with the coronavirus vaccine, the media reported. Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11. ""Over 60,000 people have signed up as volunteers, several thousand people have passed the required medical tests to be registered as potential candidates for carrying out the tests,"" Mayor Sergei Sobyanin was quoted as saying in reports on Sunday. According to Russian Tass news agency, more than 700 people have been injected with the coronavirus vaccine. ""All of them are feeling good,"" Sobyanin said. The vaccine was developed on a platform that had been used for a number of other vaccines. On August 15, the Russian Health Ministry announced the launch of the vaccine production.",RDY,en,Sify.com
2020-09-18 00:49:15-05:00,"Dr Reddy's Lab shares today hit new highs, extend weekly gains to 20%","Dr Reddy's Laboratories said it has settled a litigation with a unit of Bristol Myers Squibb.Earlier this week, it had reached an agreement to buy Russia covid vaccines",RDY,en,Livemint
2020-09-18 00:26:55-05:00,Dr Reddy's Labs Hits Record High On Settlement Of Patent Litigation,"Shares of Dr Reddy's Laboratories soared 10 percent to hit a record high of Rs 5,302.85 after the pharma company informed the settlement of their litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for REVLIM (lenalidomide)",RDY,en,Goodreturns
2020-09-17 21:43:00-05:00,"Top stocks to watch— Dr Reddy's Laboratories, HDFC Bank, TVS Motor, Vedanta, IRCTC, L&T, Bharat Forge, HAL, and more","At 8:00 am, the SGX Nifty was trading 0.07% higher, higher pointing towards a cautious start for Nifty50. Here’s a list of stocks to watch for in trade today.",RDY,en,Business Insider India
2020-09-16 08:16:00-05:00,"RDIF, Dr Reddy's to cooperate on trials, distribution of Sputnik V vaccine","The Russian Direct Investment Fund (RDIF), Russias sovereign wealth fund, and Dr Reddys Laboratories Ltd have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India",RDY,en,Business Standard
2020-09-09 01:12:11-05:00,Dr Reddy's launches Remdesivir under brand name 'Redyx' for Covid-19 treatment in India,"HYDERABAD: Dr Reddys Laboratories Ltd on Wednesday announced the launch of Remdesivir, meant for treatment of COVID-19 patients, under a brand name 'Redyx' in India.According to a press release from the drug maker, the launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddys the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India.Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms.""Dr Reddy's Redyx is available in strength of 100 mg vial,"" it said.Chief Executive Officer of Branded Markets (India and Emerging Markets), Dr Reddys Laboratories, M V Ramana said, ""We will continue our efforts to develop products that address significant unmet needs of patients.The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India.",RDY,en,Economic Times India
2020-09-04 01:49:51-05:00,'Earnings in pharma sector will double in 4-5 years',"Pharma is one of the sectors with high earnings visibility. Though stocks have rallied fast in the recent past, investors will earn earnings-led returns. Sailesh Raj Bhan, Deputy CIO Nippon Mutual Fund and Fund Manager for Nippon Pharma Fund, tells Prashant Mahesh that earnings could double within 4-5 years.The Nifty Pharma Index has moved up by 43% in the last one year. Several individual stocks like Divis Lab, IPCA have doubled. Many others like Dr reddys are up 73% and Biocon 82%. Average returns from pharma funds are 53% over the last one year. What has changed fundamentally in the space?The challenges faced in the Covid-19 pandemic have brought healthcare to the top of everyone’s mind. With just 1.6% of GDP being spent on healthcare in FY20, India is under-invested to take care of the rising demand for these services. A dramatic change in investment in both public and private sector is the need of the hour. This also presents multiple opportunities across health tech solutions, diagnostics, hospital care and medical insurance.The pharma sector has been in an improving trend after 3-4 difficult years of 2016-18.",RDY,en,Economic Times India
2020-09-03 02:42:26-05:00,Dr Reddy's launches generic attention deficit disorder drug in US market,"New Delhi: Dr Reddy's Laboratories on Thursday said it has launched Methylphenidate Hydrochloride extended-release tablets, used to treat attention deficit disorder (ADD), in the US market. The company's product is generic version of Janssen Pharmaceuticals' Concerta tablets, Dr Reddy's Laboratories said in a statement. According to IQVIA Health, the Concerta brand and generic products had US sales of around USD 1.159 billion for the most recent 12 months ending in June 2020. The Hyderabad-based firm said its product is available in strengths of 18 mg, 27 mg, 36 mg, and 54 mg tablets in bottle count sizes of 100.",RDY,en,Economic Times India
2020-08-29 07:18:00-05:00,Wockhardt Q1 net profit at ₹ 760 cr,"The company had posted a net loss of ₹36.88 crore for April-June while total income stood at ₹606.22 crore.It said that divestment of business undertaking to Dr Reddy's Laboratories was accomplished during the quarter and ₹1,483 crore has been received",RDY,en,Livemint
2020-08-27 13:23:42-05:00,What makes Divi's different from its Nifty peers?,"ET Intelligence Group: An 80% gain in the stock of Divi's Labs during the past five months has catapulted the company into the Nifty-50 Index. The Hyderabad-based pharma company, however, is quite different from peers Sun Pharma, Cipla and Dr Reddy's Labs, and predecessors Lupin and Aurobindo Pharma in the index. It is the smallest pharma company by revenues among all of them, but is trading at one of the highest valuations due to its superior profitability and unique business proposition.Unlike its peers, Divi is a pure-play active pharma ingredients (API) company and does not face the same challenges and risks as that of its peers predominantly engaged in formulations exports.77791870The company's inclusion in the benchmark index next month couldn't be better-timed. Thanks to Covid-19, the focus on APIs has increased with the pharma industry globally reducing its dependency on China. As one of the largest suppliers of APIs, Divi stands to benefit. Besides, there is a visible push to lower drug prices in the developed world and having the capabilities to manufacture APIs at low-cost becomes critical.",RDY,en,Economic Times India
2020-08-27 06:17:00-05:00,Dr Reddy's Labs launches Wilson's disease treatment capsules in US,"Pharma major Dr Reddy's Laboratories said it has launched generic Penicillamine capsules, used for treatment of Wilson's disease and cystinuria, in the US market",RDY,en,Business Standard
2020-08-27 05:22:08-05:00,Dr Reddy's launches Wilson's disease and cystinuria treatment capsules in US,"New Delhi: Pharma major Dr Reddy's Laboratories on Thursday said it has launched generic Penicillamine capsules, used for treatment of Wilson's disease and cystinuria, in the US market. The company announced the launch of Penicillamine capsules USP in the strength of 250 mg after it was approved by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a filing to the BSE. The product is a generic version of Bausch Health Companies Inc's Cuprimine capsules in the same strength, it added. According to IQVIA Health data, the Cuprimine brand and generic market had US sales of approximately USD 80 million MAT for the most recent twelve months ending in June 2020, Dr Reddy's said. The capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Shares of Dr Reddy's Laboratories on Thursday closed 0.20 per cent lower at Rs 4,429.",RDY,en,Economic Times India
2020-08-25 00:39:00-05:00,Dr Reddy's forays into hospital nutrition with Celevida Maxx in India,Dr Reddys Laboratories Ltd announced its entry into the hospital nutrition segment with the launch of 'Celevida Maxx' in India,RDY,en,Business Standard
2020-07-30 01:41:20-05:00,Dr Reddy's Labs Shares Hit All-Time High After Q1 Results,"On Thursday, shares of Dr Reddy's Laboratories rose nearly 6 percent to a new all-time high of Rs 4,544 after the company reported a higher than expected profit for the June-ended quarter. The multinational pharma company posted a 12.6",RDY,en,Goodreturns
2020-07-30 01:26:03-05:00,Dr Reddy's Labs Hits 52-Week High After Q1 Results,"On Thursday, shares of Dr Reddy's Laboratories rose nearly 5 percent to its 52-week high of Rs 4,495 after the company reported a higher than expected profit for the June-ended quarter. The multinational pharma company posted a 12.6 percent",RDY,en,Goodreturns
2020-07-29 16:30:00-05:00,Dr Reddy’s Laboratories reports 13% decline in profit at Rs 579 crore in June quarter,"However, revenue for the quarter was up by 15% to Rs 4,417.5 crore against Rs 3,843.5 crore reported during last fiscal.",RDY,en,The Financial Express
2020-07-29 07:29:00-05:00,Dr Reddys PAT down in Q1; to launch COVID-19 drugs in August,A senior official of the company said Dr Reddys is planning to export the Remdesivir to emerging and Asian markets once the product and approvals are in place.,RDY,en,The Financial Express
2020-07-29 03:56:23-05:00,Dr Reddy's Q1 result: PAT down 13% at ₹ 579.3 crore,Dr Reddy's Laboratories consolidated profit after tax for the quarter ended June 30 was down by 13% to ₹579.3 crore against ₹662.8 crore during the same quarter in FY20,RDY,en,Livemint
2020-07-29 03:31:00-05:00,Dr Reddy's Labs rallies 4% to hit a record high on healthy Q1 numbers,"The company's consolidated revenues rose 15 per cent to Rs 4,418 crore, mainly due to growth in US formulations",RDY,en,Business Standard
2020-07-29 03:05:59-05:00,DRL Q1 profit falls 13% YoY to Rs 579 crore,"Dr Reddy’s Laboratories on Wednesday posted a 12.59 per cent year-on-year (YoY) drop in net profit at Rs 579.30 crore for the quarter ended June 30. It had posted a net profit of Rs 662.80 crore in the corresponding quarter last year.Analysts in an ET NOW poll had projected the figure at Rs 498 crore.Consolidated revenue increased by 14.93 per cent YoY to Rs 4,417.50 crore during the quarter under review. Commenting on the results, Dr Reddy’s, Co-Chairman and MD, G V Prasad said ""The current quarter’s financial performance has been strong across all parameter. We have been able to serve our patients well and ensured continuity of business operations despite the challenging times.”He added that the company has started integration of the acquired business from Wockhardt and executed two important licencing arrangements for treatment options for Covid-19. At present, Dr Reddy’s is working towards bringing both these drugs to multiple markets.Shares of the company traded 3.48 per cent higher at Rs 4,191 after the announcement of the quarterly result, while the benchmark BSE Sensex was down 0.",RDY,en,Economic Times India
2020-07-29 01:31:16-05:00,Dr Reddy’s up 2% ahead of Q1 results; here’s what to expect,Emkay Global Financial Services sees 26 per cent YoY drop in net profit of Dr Reddy’s Labs on 8.1 per cent growth in revenue.,RDY,en,Economic Times India
2020-07-28 21:32:25-05:00,"Board Meetings Today: Maruti Suzuki, Bharti Airtel, SpiceJet, Dr Reddy’s Labs and Ceat","GSK Pharma, Mahindra Lifespace, Manappuram Finance and TVS Motor will announce June quarter earnings today.",RDY,en,Economic Times India
2020-07-28 20:58:00-05:00,"Stocks in the news: Bharti Airtel, Maruti, YES Bank, Dr Reddy's Labs, IndusInd Bank and Nestle India",A more than five-fold jump in provisions weighed on IndusInd Bank net profit for the June quarter,RDY,en,Economic Times India
2020-07-27 01:36:34-05:00,"Dr Reddy's Laboratories gets USFDA nod for Xeglyze lotion, used for lice treatment","New Delhi: Drug major Dr Reddy's Laboratories on Monday announced approval from the US health regulator for Xeglyze lotion, used in treatment of head lice infestation. In September 2015, Dr Reddy's Laboratories had signed a commercialisation deal with Australia's Hatchtech for the latter's prescription head lice product Xeglyze Lotion. Dr Reddy's Laboratories said it is working to commercialise this product through partners. In a regulatory filing, Dr Reddy's Laboratories announced it has received ""approval of Xeglyze (abametapir) lotion… by the US Food and Drug Administration (USFDA)"". The approval triggers the contractual pre-commercialisation milestone of USD 20 million (about Rs 149 crore) payable to Hatchtech Pty Ltd, the company added. Xeglyze is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. Shares of Dr Reddy's Laboratories were trading 0.95 per cent lower at Rs 4,025 apiece on the BSE.",RDY,en,Economic Times India
2020-07-24 12:33:30-05:00,Indian drug companies start off a price war on experimental Covid-19 drug,"MUMBAI: The price of favipiravir has crashed more than 40% in a month and is expected to fall further over the next week, as stiff competition is emerging in the market for supplying the experimental drug indicated for Covid-19 patients with mild-to-moderate symptoms.The Drug Controller General of India has this week given approval to BDR Pharmaceuticals, Optimus Pharma and Cipla to manufacture the raw materials and finished product of the antiviral developed by Japan’s Toyama Chemical. This has opened the doors for other pharma companies to procure the drug from these three manufacturers and market under their own brand names.Over the next few weeks, close to 10 drug companies including Abbott, Lupin, Micro Labs, Mcleods Pharma, Cipla, Strides Pharma and Dr Reddy’s Laboratories are expected to launch their own brands of favipiravir, despite inconclusive evidence of its effectiveness.Currently the only company marketing favipiravir in India is Glenmark Pharmaceuticals. The Mumbai-based company launched the drug a month ago under the FabiFlu brand, at Rs 103 a tablet of 200 mg.",RDY,en,Economic Times India
2020-07-14 11:34:00-05:00,Biophore gets DCGI nod to make favipiravir,"MUMBAI / HYDERABAD: Indian drugmakers’ interest in launching their versions of antiviral drug favipiravir as a treatment for Covid-19 has not waned even after a recent study said the drug’s efficacy in treating mild symptoms of the disease remains inconclusive.On Tuesday, Hyderabad-based Biophore India Pharmaceuticals said it has received approval from the Drug Controller General of India (DGCI) to produce favipiravir as treatment for mild to moderate symptoms of Covid-19 for exports. The company is waiting for a nod from the drug controller to market the drug in India. Interest in manufacturing the drug seems unaffected despite a recent study in Japan saying that the effectiveness of the drug in treating Covid-19 remains inconclusive.There are at least four other Indian drug makers which are awaiting clearance from the DGCI to manufacture and market favipiravir in India. Among them are Dr Reddys, Strides Pharma, BDR Pharma and Optimus Pharma. Some of these companies are already exporting the drug to Turkey, Russia and Bangladesh.Favipiravir, first brought out by a subsidiary of Fujifilm as ‘Avigan’ in 2014, gained attention in March this year after reports from China said it appeared to help in the recovery of Covid-19 patients with mild to moderate symptoms.Last week, an observational study by Japan’s Fujita University said the effectiveness of the drug in treating Covid-19 remains inconclusive.The researchers wrote that given over 80% of Covid-19 patients have mild symptoms, which often improve with supportive therapy, caution is required in interpreting the efficacy of favipiravir based on the data presented here.",RDY,en,Economic Times India
2020-07-06 03:16:00-05:00,Overall performance may be quite volatile in FY21 due to coronavirus: Dr Reddy’s,"Dr Reddy's Laboratories expects its overall performance to be ""quite volatile"" in the current fiscal with uncertainties related to COVID-19 set to increase during the period, the company said in its Annual Report for 2019-20.",RDY,en,The Financial Express
2020-07-06 02:00:03-05:00,"Angel Broking has a buy call on Dr Reddy's Labs, target price Rs 4,570",The brokerage believes the acquisition of the domestic business of Wockhardt Pharma is value accretive for the company.,RDY,en,Economic Times India
2020-07-02 06:56:50-05:00,Pharma major Mylan gets go-ahead to make remdesivir for 'restricted emergency use',"NEW DELHI: After Hetero and Cipla, another pharmaceutical major Mylan was given permission by India's drug regulator on Thursday to manufacture and market the anti-viral drug remdesivir for ""restricted emergency use"" on hospitalised COVID-19 patients, official sources said.Written informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting of serious adverse events have to be submitted.On June 21, Hetero and Cipla were given permission to manufacture and market the drug on the same conditions.The Union Health ministry in its 'Clinical Management Protocols for COVID-19' recommended the use of the drug in COVID-19 patients with moderate stages of the illness (those on oxygen support).The drug has been included as an €œinvestigational therapy€? only for restricted emergency use purposes.It is not recommended for those with severe renal impairment and high level of liver enzymes, pregnant and lactating women, and those below 12 years, the document stated.The drug, administered in the form of an injection, should be given at a dose of 200 mg on day one followed by 100 mg daily for five days.""The approval was given by the CDSCO on Thursday,"" an official source in the know of the developments told PTI.Mylan had already entered into non-exclusive licensing agreements with Gilead Sciences, which is the patent holder of the drug remdesivir.US pharma giant, Gilead Sciences, had applied to the Indian drug regulatory agency, Central Drugs Standard Control Organisation (CDSCO), for import and marketing of remdesivir on May 29.After due deliberations, permission under emergency use authorisation was granted by Drug Controller General of India (DCGI) on June 1 in the interest of patient safety and obtaining further data.On June 21, Hetero and Cipla were given permission to manufacture the drug.",RDY,en,Economic Times India
2020-07-01 22:36:00-05:00,"Stocks in focus: Axis Bank, Abbott India, Pfizer, Hero MotoCorp, Dr Reddy’s Laboratories, India Cements","Aarti Industries, Ipca LabAdani Gas, ICICI General Insurance, PI Industries, and Trent, L&T Infotech, HDFC AMC, and Deepak Nitrite are among 11 stocks that are likely to be included in the futures & options (F&O) segment",RDY,en,The Financial Express
2020-07-01 21:48:28-05:00,"Stocks in the news: Axis Bank, Dr Reddy's Labs, Adani Ports, Hero MotoCorp and Coal India",Uflex has reported a 43.30 per cent rise in consolidated net profit at Rs 100.90 crore for the fourth quarter.,RDY,en,Economic Times India
2020-07-01 02:10:00-05:00,Fujifilm to partner Dr Reddy's to sell Avigan as coronavirus treatment,"Japan's Fujifilm Holdings Corp said it was partnering with Dr Reddy's Labs to sell the anti-flu drug Avigan in India and elsewhere to treat Covid-19, the respiratory disease caused by the coronavirus.",RDY,en,Business Standard
2020-06-28 04:01:01-05:00,Expect to launch 25 products in US this fiscal: Dr Reddy's,"Dr Reddy's Laboratories expects to launch 25 products in the US market in the current financial year, according to a top company official. The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year. ""On a full-year basis (2019-20), we launched 27 products, including four re-launch of the earlier discontinued products. We expect the new launches momentum to continue during the year with about 25 product launches lined up despite uncertainty due to COVID-19,"" Dr Reddy's Laboratories CEO Erez Israeli said in an analyst call. As of March 31, 2020, the company has 99 cumulative filings pending for approval with the US Food and Drug Administration (USFDA), including two new drug approvals (NDAs), he added. ""We also filed 59 drug master files globally, including seven filings made in the US,"" Israeli said. On new pipeline of products, he said the company is also working on a few molecules related to COVID-19.",RDY,en,Economic Times India
2020-06-25 03:04:38-05:00,Dr Reddy Laboratories : to present at the Barclays Spec Pharma Fireside Chat Series | MarketScreener,"Press Release CONTACT DR. REDDY'S LABORATORIES LTD. INVESTOR RELATIONSMEDIA RELATIONS … | June 25, 2020",RDY,en,MarketScreener
2020-06-21 03:00:04-05:00,7 pharma cos in list of 8 largecaps which hit 52-wk highs in June,"When going gets tough, the tough get going and how! As many as 10 largecap stocks have hit record highs in June so far and another eight reached 52-week highs even as the benchmark indices are still around 18% away from their January peaks. This reflects the selective approach of investors who are favouring companies with a combination of various factors such as a solid track record, strong leadership, resilient performance during the current economic downturn, and ability to improve balance sheet strength.Each of these stocks have gained in double digits over the past three months exceeding the 23% gain in the S&P BSE Sensex. The 10 stocks that hit a record high include Reliance Industries (RIL), Britannia Industries, Adani Green Energy, Divis Laboratories, Muthoot Finance, Biocon, Bayer CropScience, PI Industries, Coromandel International, and Syngene International.The stock of RIL, the largest among them by market capitalisation and the country’s biggest conglomerate with interests in energy, retail and telecom, has doubled in the past three months.",RDY,en,Economic Times India
2020-06-18 01:45:39-05:00,Share market update: Pharma shares mixed; Dr Reddy's Labs up 1%,The Nifty Pharma index was trading 0.05 per cent up at 9982.15.,RDY,en,Economic Times India
2020-06-16 00:29:01-05:00,FDA warns against co-administration of remdesivir with CQ or HCQ for COVID-19 patients,"Hyderabad: The US Food and Drug Administration (USFDA) warned healthcare providers against co-administration of Gilead Sciences remdesivir, which received emergency use authorization for COVID-19 patients, along with chloroquine phosphate or hydroxychloroquine sulfate as it may reduce the efficacy of the former. The FDA said though the agency is not aware of instances of this reduced activity occurring in the clinical setting but, is continuing to evaluate all data related to remdesivir. ""FDA is warning health care providers that co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended as it may result in reduced antiviral activity of remdesivir. The agency is not aware of instances of this reduced activity occurring in the clinical setting but is continuing to evaluate all data related to remdesivir,"" the FDA said in a statement. Following an evaluation of the emergency use authorization criteria and scientific evidence available, the FDA issued an emergency use authorization (EUA) in May 2020 allowing remdesivir to be distributed in the US to treat COVID-19 in adults and pediatric patients hospitalised with severe disease.",RDY,en,Economic Times India
2020-06-15 07:09:14-05:00,Dr Reddy’s Labs Signs Licensing Agreement For Gilead’s Remdesivir,Dr Reddy’s Laboratories Ltd. (RDY) announced that it has entered into a non-exclusive licensing agreement to manufacture and sell Gilead Sciences Inc. The post Dr Reddy’s Labs Signs Licensing Agreement For Gilead’s Remdesivir appeared first on Smarter Analyst .,RDY,en,Smarter Analyst
2020-06-14 22:14:00-05:00,"Stocks in news: Hindalco Industries, Dr Reddys, Lupin, PNB Housing, BHEL, UTI AMC, Eicher Motors, RIL, MCX","Stocks to watch today on June 15: Hindalco Industries, Dr Reddys, Lupin, PNB Housing, BHEL, UTI AMC, Eicher Motors, RIL, MCX among others are the top stocks to watch out for in Monday's trading session",RDY,en,Business Today
2020-06-14 21:07:14-05:00,"Stocks in the news: Reliance Industries, Vodafone Idea, Tata Motors, Dr Reddy's Labs and BHEL","CSB Bank, JK Tyre, Pfizer, Shalby, Shoppers Stop and Ramky Infra are among companies which will announce Q4 results today.",RDY,en,Economic Times India
2020-06-13 04:51:50-05:00,Dr Reddy's inks pact with Gilead to manufacture COVID-19 drug,"New Delhi: Dr Reddy's Laboratories on Saturday said it has inked pact with US-based Gilead Sciences to manufacture and market Remdesivir - a potential treatment for COVID-19 - in 127 countries, including India. As per the non-exclusive licensing agreement, Gilead will grant the Hyderabad-based drug maker the right to register and manufacture its investigational drug Remdesivir in 127 countries, Dr Reddy's Laboratories said in a statement. The company will receive technology transfer from Gilead for manufacturing of the drug, it added. Dr Reddy's would need to scale up manufacturing and obtain regulatory approval for marketing of this drug in respective countries, the company said. Remdesivir, an investigational antiviral therapy developed by Gilead, has received Emergency Use Authorisation (EUA) by the US Food and Drug Administration (USFDA) to treat COVID-19.",RDY,en,Economic Times India
2020-06-09 21:15:00-05:00,"Nifty outlook and stock pick by HDFC Sec: Buy Dr Reddy's Labs, L&T Infotech","Looking at the strong setup on the medium term charts, it would be advisable to buy Nifty around 9,900, for the upside target of 10,300.",RDY,en,Business Standard
2020-06-08 07:00:57-05:00,Midatech enters research collaboration with Dr Reddy's,"Biotechnology research and development company Midatech Pharma has entered into a research collaboration with generic drugs giant Dr Reddy's Laboratories, it announced on Monday.",RDY,en,Share Cast
2020-06-07 23:48:00-05:00,Google Cloud India hires NetApp veteran Anil Valluri,"New Delhi, June 8 (IANS) Google Cloud on Monday announced to appoint global Cloud data services company NetApp veteran Anil Valluri as Senior Director for Google Cloud in India. Valluri would help Google Cloud deepen customer engagement, expand on its strategic partnerships and deliver advanced solutions to help companies in India accelerate their data-led innovation. ""Valluri has led some of the biggest technology MNCs in India and his experience will be invaluable as we continue our charter to help companies solve their most complex business and technology challenges,"" Karan Bajwa, Managing Director, Google Cloud India, said in a statement. Google Cloud has a rich list of customers in India, including Dr Reddy's Laboratories, Indiamart, Hero Motocorp, ICICI Prudential, L&T Finance, LIC HFL, Manipal Hospitals, OYO Hotels and Homes, Truecaller, Wipro and others. In March, the company announced plans to expand its presence in India by launching a cloud region in Delhi, adding to its Mumbai region which was opened in 2017. ""Cloud is the next big transition in the technology industry and Google has been making major strides in this space.",RDY,en,Sify.com
2020-06-03 01:41:21-05:00,Share market update: Pharma shares climb; Dr Reddy's Labs gains 2%,The Nifty Pharma index was trading 0.76 per cent up at 9908.5.,RDY,en,Economic Times India
2020-05-31 21:51:01-05:00,"Buy Dr Reddy's Laboratories, target price Rs 4,250: Chandan Taparia",The analyst suggested a stoploss at Rs 3980.,RDY,en,Economic Times India
2020-05-29 06:21:05-05:00,"From NPCI to Fluid AI, Google Cloud preparing Indian firms for new normal","New Delhi, May 29 (IANS) As businesses around the globe adapt to the new normal, Google Cloud is helping a diverse set of organisations, from the National Payments Corporation of India (NPCI) to Artificial Intelligence (AI)-based company Fluid AI efficiently manage their workloads across remote locations, Karan Bajwa, Managing Director, Google Cloud India, said on Friday. Bajwa, a senior industry veteran with over three decades of leadership experience who joined Google Cloud in March this year, said that most businesses and users in the country depend on Google Cloud to stay connected and get work done. ""As Covid-19 runs its course, we at Google Cloud are working hard to deliver technology and business solutions to help millions of people stay connected. We believe today more than ever, we need to collaborate and innovate and build new features to make our tools helpful, secure and safe,"" he said in a blog post. Bajwa said that today, employees of NPCI have been able to efficiently manage work across remote locations where employees can securely work and collaborate with colleagues, clients and stakeholders. ""Kochi-based conglomerate Muthoot Group, one of the largest financial services providers in the country has been using G Suite's collaboration tools to stay connected and carry business as usual during the lockdown period,"" he informed.",RDY,en,Sify.com
2020-05-26 02:28:12-05:00,"Dr Reddy Laboratories : Outcome of Board Meeting – May 20, 2020 | MarketScreener","1 6,602 … | May 26, 2020",RDY,en,MarketScreener
2020-05-25 21:19:34-05:00,"Buy Dr Reddy's Laboratories, target price Rs 4,210: Dharmesh Shah",The analyst suggested a stoploss at Rs 3730.,RDY,en,Economic Times India
2020-05-22 03:52:05-05:00,Dr Reddy Laboratories : Grant of Stock Options | MarketScreener,"May 21, 2020 The Secretary BSE Limited National Stock Exchange of India Ltd. New York Stock… | May 22, 2020",RDY,en,MarketScreener
2020-05-21 02:56:50-05:00,"Hold Dr Reddy's Labs, target price Rs 3,962: ICICI Securities",The brokerage raised its EPS estimates by 1-5 per cent for FY21E-FY22E to factor-in lower depreciation charge and reduced tax rate.,RDY,en,Economic Times India
2020-05-19 22:17:00-05:00,"Reliance Industries, Bajaj Auto, UltraTech Cement, among other stocks to hog limelight today","Bajaj Auto, Dr Reddy's Laboratories, JK Lakshmi Cement, JSW Energy, Ultratech Cement, Jubilant Foodworks, Ajanta Pharma, Kalpataru Power, and Tata Steel Bsl are among 22 companies which are scheduled to announce their March quarter earnings today.",RDY,en,The Financial Express
2020-05-19 21:32:23-05:00,"Board Meetings Today: Bajaj Auto, Dr Reddy's Labs, Ultratech Cement, JSW Energy and Jubilant Foodworks,","Ajanta Pharma, Kalpataru Power, Matromony.com and JK Lakshmi Cement are some of the companies which will disclose their March quarter results today.",RDY,en,Economic Times India
2020-05-15 18:20:06-05:00,USFDA Looks for Ways to Speed up Plant Inspections,"Mumbai: The US Food and Drug Administration is considering alternative approaches for inspections of manufacturing sites, acting upon requests from several companies, including Indian drug makers, to address the issue.The move has been triggered by the shortage of drugs — most of them supplied by Indian generic drug companies — that the US faces during the Covid-19 pandemic. The Indian Pharmaceutical Alliance has asked the FDA last month to find a solution for inspecting the manufacturing plants of its members.“During Covid-19, the US Food and Drug Administration will continue to utilise and implement additional alternative inspection tools and approaches while postponing domestic and foreign routine surveillance inspections. This will continue as local, national and international conditions warrant, with the exception of certain mission-critical inspections,” the US regulator said in a statement dated May 11.Sudarshan Jain, secretary-general of the IPA, said the organisation would not like to comment on the matter because certain communication between regulators and companies needs to be private for the sake of national interest.75766709Life sciences and biotech website Fiercepharma reported on Thursday that the IPA had asked for “virtual reviews of facilities that are new, are slated to produce a new class of drugs or have completed a corrective action plan following a previous inspection failure.”The lockdown in India and other countries has created logistical issues that have hampered exports and led to drug shortages.",RDY,en,Economic Times India
2020-05-10 21:19:09-05:00,"Neutral on Dr Reddy's Laboratories, target price Rs 3,410: Haitong Securities",The company received an NDA approval for an anti-migraine drug Elyxyb from the US FDA.,RDY,en,Economic Times India
2020-05-10 20:28:45-05:00,"Analyst Calls: RBL Bank, Dr Reddy's Laboratories",IIFL has a buy rating on RBL Bank with a target price of Rs 190.,RDY,en,Economic Times India
2020-05-08 01:36:20-05:00,Share market update: Pharma shares rise; Dr Reddy's Labs gain 3%,The Nifty Pharma index was trading 1.84 per cent up at 9316.15 .,RDY,en,Economic Times India
2020-05-04 02:16:00-05:00,"Sensex slides to 31K, Nifty loses 500 points: 5 factors behind market crash today","UPL, GAIL, Vedanta, Hindalco, Tata Motors, ICICI Bank were among the top losers today, while Cipla, Sun Pharma, Dr Reddy's Laboratories were among the top gainers on Nifty.",RDY,en,Business Today
2020-04-21 22:17:09-05:00,"Buy Dr Reddy's Laboratories, target price Rs 4,250: Suruchi Kapoor",The analyst suggested a stoploss at Rs 3875 .,RDY,en,Economic Times India
2020-04-21 21:49:19-05:00,"Buy Dr Reddy's Labs, target price Rs 4,426: Nomura",Nomura said Dr Reddy's near term earnings are dependent on North America generics and it expects 52 per cent of FY22 EPS from the region.,RDY,en,Economic Times India
2020-04-21 20:44:12-05:00,"Analyst Calls: SBI Cards, Kotak Bank, Dr Reddy's Labs",Bank of America Securities has initiated coverage on SBI Cards with a buy rating and target price of ₹680.,RDY,en,Economic Times India
2020-04-21 04:42:00-05:00,"Dr Reddy's Labs hits over 4-year high, surges 62% from March low","Analysts believe Dr Reddy's US business, which has been facing revenue pressure, is likely to rebound with new product launches and the gradual normalization of price erosion in its key products.",RDY,en,Business Standard
2020-04-15 02:33:26-05:00,"Buy Dr Reddy's Labs, target price Rs 4,382: Anand Rathi","Apart from a strong product profile, the company benefits from a diverse geographic presence with major markets being USA, India, Russia, CIS regions and Europe.",RDY,en,Economic Times India
2020-04-13 02:53:03-05:00,Dr Reddy Laboratories : announces the launch of Invista® (dasatinib) in India | MarketScreener,"Press Release … | April 13, 2020",RDY,en,MarketScreener
2020-04-06 21:38:10-05:00,"Buy Dr Reddy's Laboratories, target price Rs 3,270: Dharmesh Shah",The analyst suggested a stoploss at Rs 3065 .,RDY,en,Economic Times India
2020-03-16 07:00:52-05:00,"Nothing to fuel growth in healthcare, pharma sectors: Dr Reddy's","Hyderabad: Pharma major Dr Reddy's Laboratories Ltd on Friday said that the Union Budget 2019-20 has nothing to fuel growth in the healthcare and pharma sectors. ""The expectations from the Union Budget 2019 were that of a bold reformist budget, however, it turned out to be an incremental budget at best,"" said Satish Reddy, Chairman, Dr. Reddy's Laboratories ""The emphasis on start-ups and on the education sector is a good move. However, there was nothing to fuel growth in the healthcare and pharma sectors, which is disappointing. ""I was particularly keen on seeing a change in the weighted deduction for R&D which did not happen. A positive policy move of this kind would have spurred R&D and innovation in pharma and other sectors,"" he added. Apollo Group of Hospitals feels that the budget has a number of measures which will reduce illness and promote wellness in the community. Dr. K. Hari Prasad, President, Hospitals Division, Apollo believes that open defecation free India, clean fuel for cooking, emphasis on electric vehicles, clean drinking water, promotion of yoga and 'Khelo India' initiative will contribute to the government's vision of a healthy India in a decade.",RDY,en,Sify.com
2020-02-16 21:43:56-05:00,"Stocks in the news: Airtel, NIIT Tech, Dr Reddy's Labs, DLF, BPCL, IDBI Bank and Vodafone Idea",Zydus Cadila said it has initiated an accelerated research programme for developing a vaccine for coronavirus.,RDY,en,The Economic Times India
2020-02-16 08:11:00-05:00,USFDA seeks voluntary action at Dr Reddy's Andhra Pradesh unit,Drug major Dr Reddy's Laboratories on Sunday said the United States Food and Drug Administration (USFDA) has asked it to initiate voluntary action at its Duvvada facility in Andhra Pradesh.,RDY,en,Business Today
2020-02-12 23:27:00-05:00,Wockhardt tanks 5% after it sells domestic branded ops to Dr Reddy's Labs,"Read more about Wockhardt tanks 5% after it sells domestic branded ops to Dr Reddy's Labs on Business Standard. The deal, which could fetch a consideration amount of Rs 1,850 crore, is expected to close in the first quarter of financial year 2020-21, Wockhardt added.",RDY,en,Business Standard
2020-02-12 21:26:57-05:00,Dr Reddy’s not as big as it should be in India...we want to grow more: GV Prasad,"Hyderabad-based Dr Reddy's Laboratories sprung a surprise on Wednesday when it announced that it will acquire the domestic business of Wockhardt Pharma for Rs 1,850 crore. The deal signifies Dr Reddy's de-risking strategy with regards to its US business, which has taken a hit because of regulatory actions. GV Prasad, CEO of Dr Reddy's, said the future capital allocation by the company will come into emerging markets such as India. Edited excerpts:",RDY,en,The Economic Times India
2020-01-28 07:27:56-05:00,"63 stocks hit 52-week highs on NSE, even as Sensex, Nifty end deep in red","As many as 63 scrips including Dr Reddy's Laboratories, IRCTC, MRF, Ujjivan Financial Services, Jubilant Industries and Indraprastha Gas hit a new 52-week high on NSE in Tuesday's trade",RDY,en,The Financial Express
2020-01-26 21:37:28-05:00,"Stocks in the news: HDFC, Dr Reddy's Labs, ICICI Bank, JSW Steel and Cipla",DCB Bank reported an increase of 12.31 per cent in its net profit at Rs 96.70 crore for December quarter.,RDY,en,The Economic Times India
2020-01-17 04:57:00-05:00,"Dr Reddy's Labs nears 2-year high, regains Rs 50,000 crore m-cap","In the first 11 trading days of the current calendar year, Dr Reddy's has outperformed the market by surging 6 per cent on expectations of earnings improvement.",RDY,en,Business Standard
2020-01-13 08:03:10-05:00,Dr Reddy Laboratories : to present at the 38th Annual J.P. Morgan Healthcare Conference | MarketScreener,"Press Release … | January 13, 2020",RDY,en,MarketScreener
2020-01-10 03:19:41-05:00,"Citi turns positive on pharma; Aurobindo, Biocon top bets","Citi has upgraded Dr Reddy Laboratories to ‘buy’ from ‘sell’ earlier. It has a target of Rs 3,380 on the stock.",RDY,en,The Economic Times India
2020-01-06 22:01:39-05:00,"'BUY' or 'SELL' ideas from experts for Tuesday, 7 January, 2020",Dr Reddy's Labs is a 'Buy' call with a target price of Rs 2980 and a stop loss of Rs 2855.,RDY,en,The Economic Times India
2019-12-18 21:56:23-05:00,"Emkay Global has sell on Dr Reddy's Labs, target price Rs 2,580",The brokerage rating came after Prasco announced the authorised generic launch of Nuvaring. This is the second generic launch for the product within a week’s time.,RDY,en,The Economic Times India
2019-12-12 23:00:03-05:00,"Sensex jumps 284 points in opening trade, Nifty above 12,000",Gains in the domestic market was led by banking and metal stocks.Dr Reddy's Laboratories fell 4%,RDY,en,Livemint
2019-12-12 22:03:34-05:00,"Stocks in Focus on December 13: Dr Reddy's, Bharti Airtel to Maruti Suzuki; here are the 5 Newsmakers of the Day","Dr Reddy's Laboratories: Dr Reddy's will be in focus today as NYSE-listed drugmaker Amneal Pharmaceuticals Inc. received the US Food and Drug Administration (USFDA) to launch Generic version of Merck & Co's NuvaRing, pregnancy prevention drug. Get more Markets News and Business News on Zee Business.",RDY,en,Zee Business
2019-11-26 00:51:00-05:00,"Dr Reddy's Labs extends gains for second straight day, hits 33-month high","Read more about Dr Reddy's Labs extends gains for second straight day, hits 33-month high on Business Standard. Analysts at SBICAP Securities upgraded the stock with 'buy' rating and target price of Rs 3,200 per share",RDY,en,Business Standard
2019-11-20 21:46:13-05:00,"SBI Cap Securities upgrades Dr Reddy's Labs to buy, target price Rs 3,200",Buy Dr. Reddy's Laboratories Ltd. at a price target of Rs 3200.0 .,RDY,en,The Economic Times India
2019-11-20 03:06:00-05:00,Nifty Pharma index hits two-month high; Sun Pharma surges 7%,"Read more about Nifty Pharma index hits two-month high; Sun Pharma surges 7% on Business Standard. Among other individual stocks, Lupin, Dr Reddy's Laboratories, Divi's Laboratories and Aurobindo Pharma from the Nifty Pharma index were up 3 per cent each on the NSE.",RDY,en,Business Standard
2019-11-01 03:30:01-05:00,Dr Reddy Laboratories : . Reddy's Q2 & H1 FY20 Financial Results | MarketScreener,"Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and the half year ended September 30, 2019 under International Financial Reporting Standards …. | November 1, 2019",RDY,en,MarketScreener
2019-10-28 21:39:09-05:00,"Stocks in the news: RIL, Infosys, ICICI Bank, Bharti Airtel and Dr Reddy's Labs","MCA has sought information on the whistleblower complaint, made against Infosys management.",RDY,en,The Economic Times India
2019-09-25 21:49:07-05:00,GSK to recall Ranitidine from India after regulator alert,"NEW DELHI: British drugmaker GlaxoSmithKline on Wednesday said it is recalling heartburn drug Ranitidine from India, a day after the country’s drug regulator asked pharma companies to check their products for carcinogen.“As a precautionary action, GSK has made the decision to initiate a voluntary recall (pharmacy/retail level recall) of Zinetac Tablets 150 mg and 300 mg products manufactured in India using API sourced from Saraca Laboratories Ltd,” a GSK spokesperson said in a statement.Earlier this month, the US FDA had raised a global alarm over the presence of a probable cancer causing substance—NDMA or N-Niteosodimethylamine—in some Ranitidine medicines.GSK manufactures Ranitidine Hydrochloride IP Tablets 150 mg and 300 mg (Zinetac) using API from Hyderabad-based Saraca Laboratories and another supplier, SMS Lifesciences India Ltd, for supply to the Indian market.Subsequently, Saraca Laboratories was notified by the European Directorate for the Quality of Medicines (EDQM) that its certificate of suitability for Ranitidine Hydrochloride has been suspended with immediate effect.GSK has been contacted by the Indian drug regulatory authority regarding the detection of genotoxic nitrosamine NDMA in Ranitidine products.“Based on the information received and correspondence with regulatory authorities, GSK made the decision to suspend the release, distribution and supply of all dose forms of Ranitidine Hydrochloride products to all markets, including India, as a precautionary action pending the outcome of ongoing tests and investigations,” added the spokesperson, clarifying that the product manufactured using API from SMS Lifesciences will not be recalled from the market at this point of time.",RDY,en,The Economic Times India
2019-09-24 22:15:59-05:00,Popular antacid Ranitidine under cancer watch,"By Teena ThackerNew Delhi: Indian authorities are closely monitoring the sale of heartburn drug Ranitidine after the US drug regulator said it had found a cancer-causing impurity called N-nitrosodimethylanine (NDMA) in some products containing Ranitidine.Ranitidine is a commonly prescribed medicine for countering acidity and is on the World Health Organisation’s ‘Model List of Essential Medicines’. In India, a host of companies including GalxoSmithKline, JB Chemicals, Cadila Pharma, Zydus Cadila, Dr Reddy’s, Sun Pharmaceuticals sell over 180 versions of the drug. The market size for Ranitidine brand in India is Rs 688.6 crore, as per data shared by AIOCD PharmaTrac.To ensure patient safety, the Drug Controller General of India (DCGI) on Tuesday directed state drug regulators to ask pharmaceutical companies to check their products for the carcinogen. It also asked them to ensure that the drug is sold only under prescription.“The drug Ranitidine is approved for multiple indications in the country and is available in various formulations including tablets, injections, etc.",RDY,en,The Economic Times India
2019-09-22 21:43:38-05:00,"Stocks in the news: YES Bank, Petronet LNG, Cipla, RCap and Dr Reddy's Labs",Thomas Cook India said it is not related with UK-based Thomas Cook PLC.,RDY,en,The Economic Times India
2019-09-12 21:42:21-05:00,"Stocks in the news: SBI Life, Biocon, L&T, Dr Reddy's Labs and Manpasand Beverages",Power Grid said it has bagged an inter-state power transmission project under a tariff-based competitive bidding.,RDY,en,The Economic Times India
2019-09-08 22:06:04-05:00,"Centrum Broking maintains buy on Dr Reddy’s, target price Rs 3,000",Buy Dr. Reddy's Laboratories Ltd. at a price target of Rs 3000.0 .,RDY,en,The Economic Times India
2019-08-20 21:42:41-05:00,"Stocks in the news: Dr Reddy's Labs, HFCL, YES Bank, Max Financial, MCX and Biocon",Analjit Singh is in talks to sell a 10% stake in Max Financial Services.,RDY,en,The Economic Times India
2019-08-14 02:15:20-05:00,Dr Reddy's Labs slumps 8% as USFDA hands out complete response letter,The stock has fallen 2.3 per cent as of last close this year.,RDY,en,The Economic Times India
2019-08-12 00:15:37-05:00,Investors can start accumulating top largecaps & midcaps,"For investment perspective Adani Port, L&T, Dr Reddy’s, Titan, UPL are good stocks.",RDY,en,The Economic Times India
2019-08-11 03:08:15-05:00,Meet the highest paid pharma executive,"Chairman and Managing Director of city-based pharma company C Murali K Divi is the highest paid executive of the Indian pharma industry with Rs 58.8 crore remuneration which includes salary and commission in 2018-19.According to Divis latest annual report, Murali Divi, the promoter-executive,was given a hike of 46.3 per cent in his remuneration over the previous fiscal.The companyoffered nearly Rs 30 crore to its Executive Director N V Ramana and over Rs 20 crore to whole-time director Kiran S. Divi, son of Murali Divi, towards remunerations in the last fiscal.Murali Divi received close to Rs 57.61 crore through commissions for the year.In FY18, he had received Rs 40.20 crore towards remuneration which included commission of Rs 39 crore.The percentage increase in the median remuneration for the employees of the company for FY19 was 3.96 per cent.The drug maker clocked Rs 1,333 crore profit after tax (PAT) on Rs 5,036 crore revenues for the year 2018-19.When it comes to other pharma players, Dilip Shanghvi, founder and managing director of countrys largest drug firm Sun Pharmatook home just Rs one as salary and Rs 2,62,800 as perks during FY19.",RDY,en,The Economic Times India
2019-08-09 18:06:21-05:00,Eli Lilly wins Fed Circuit decision fending off generic Alimta,Eli Lilly and Company won a federal appeals court decision on Friday that protects its chemotherapy drug Alimta from generic competition from Pfizer Inc and Dr Reddy's Laboratories Ltd.,RDY,en,Reuters
2019-07-30 03:36:03-05:00,Warning letter woes: Dr Reddy's expects FDA inspection of AP plant by year-end,"Hyderabad: Dr Reddy's Laboratories was expecting an inspection of its Active Pharmaceuticals Ingredients (API) plant at Srikakulam in Andhra Pradesh by the US Food and Drug Administration officials by the end of this year, a top company official said on Tuesday. ""On the regulatory front, the API plant at Miryalaguda was given an Establishment Inspection Report (EIR) in 2017 resolving the earlier warning letter. We also received EIR for the injectable site at the Duvvada and we are awaiting for CTO VI site at Srikakulam. And based on discussions, we expect an inspection ( by the FDA) later this year and hopeful for the resolution of the matter,"" Co-Chairman, Managing Director and CEO GV Prasad told shareholder in the Annual General Meeting held here. The USFDA had issued warning letter in November 2015 relating to Current Good Manufacturing Practice (CGMP) deviations at DR Reddy's API manufacturing facilities at Srikakulam in AP and Miryalaguda in Telangana besides its oncology formulation facility at Duvvada, Visakhapatnam.",RDY,en,The Economic Times India
2019-07-30 00:00:16-05:00,Dr Reddy’s Lab shares up post Q1 results; should you invest?,"Global brokerage firm CLSA maintained ‘Buy’ on DRL with a target price of Rs 3,330.",RDY,en,The Economic Times India
2019-07-29 02:52:12-05:00,"Dr Reddy’s Labs down ahead of Q1 results, here’s what to expect",Kotak Institutional Equities believes that the pharma company may report 49.70 per cent year-on-year rise in reported profit after tax for the quarter under review.,RDY,en,The Economic Times India
2019-07-28 23:12:23-05:00,"Nifty likely to trade in 11,000-11,550 range","Axis Bank, Dr Reddy’s, Hero MotoCorp, ICICI Prudential Life stocks look good for the short term.",RDY,en,The Economic Times India
2019-07-15 23:44:25-05:00,Hemang Jani on 4 spaces to hide in a slowing market,"Some of the corporate lenders, cement and some of the domestic oriented construction companies, select pharma are the areas that one can really hide in the current environment when things are not looking too great, says Hemang Jani, Senior VP, Sharekhan. Excerpts from an interview with ETNOW.Shareholders are getting a little bit disconnected with the overall market right now, given that volatility has been at a low, there is no decisive direction and every time we are talking to experts, the indication is that the undertone of the market continues to remain rather negative. What does one do at a time like this?Given the slowdown that we are witnessing in the domestic economy and the quarterly earnings season, it is not likely to throw up many surprises. In that kind of a backdrop, it would be hard to imagine that we are going to have some strength in the market. The only positive takeaway that we are seeing at this point of time is that you are going to have an interest rate cut both in the global economy as well as in the domestic market.",RDY,en,The Economic Times India
2019-07-12 06:27:18-05:00,USFDA issues 5 observations to Dr Reddy's plant in Hyd,"NEW DELHI: Dr Reddy's Laboratories said the US health regulator has issued five observations after audit of a company's plant in Hyderabad.""The audit of our active pharmaceutical ingredient (API) manufacturing plant 2 at Bollaram, Hyderabad by the United States Food and Drug Administration (USFDA), has been completed today,"" Dr Reddy's said in a filing to BSE.The company has been issued a Form 483 with 5 observations, it added.""We will address them comprehensively within the stipulated timeline,"" Dr Reddy's said. It however did not provide any details about the observations made by the regulator.As per the USFDA, Form 483 notifies the company's management of objectionable conditions.It is issued to the firm's management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. Untitled Carousel 70186763 70141399 Shares of Dr Reddy's Labs were trading at Rs 2,627.",RDY,en,The Economic Times India
2019-07-07 04:42:02-05:00,Price erosion symptoms: Dr Reddy's Laboratories plans to launch value-added drugs in US,"Maintaining that pricing pressure will continue in the US market, Dr Reddy's Laboratories has said the company plans to launch several value-added products this fiscal tooffset the persisting problem.As part of the diversification and new market entry strategy, DRL plans to re-focus some of its Research and Development resources to service the high potential branded generics markets such as China, Russia and other emerging markets.""We believe that pricing pressures will continue to affect all players in generics in the US. Overcoming this necessitates a robust pipeline of complex formulations with limited competition a pipeline that allows your company to introduce several value-added products each year, and thus make up for price erosions on the earlier launched products,"" K Satish Reddy and GV Prasad, chairman and co-chairman respectively said in the latest annual report.As many as 110 generic filings awaiting approval from the USFDA and the company has to leverage this and ensure that they succeed in delivering these products, molecule by molecule, to the US on the due dates, they said.",RDY,en,The Economic Times India
2019-06-25 00:12:26-05:00,Park your money in IT & corporate banks now: Abhimanyu Sofat,"Unless more money comes in, we do not see any big uptick in the market in the next couple of weeks at least, says Abhimanyu Sofat, VP-Research, IIFL. Excerpts form his interview with ETNOW. What is your view on Bitcoin, gold and 10-year papers?The yield curve has been steepening in the Indian market also and the interest rates are coming down - which is a kind of conundrum. There is clearly some doubt in terms of the relationship between the asset classes. We try to correlate the GDP numbers with tax numbers which are coming. Right now, the problem in case of India is that we have gone through a large cycle every year but growth never seems to come about. The situation especially in the last couple of weeks seems to reflect the mindset that the government may not be aggressively looking at relieving the short-term pain, not only in the NBFC sector but even on the manufacturing and other sectors.On the mining side, we have been importing a lot of natural resources which typically have one of the largest reserves.",RDY,en,The Economic Times India
2019-06-14 16:25:00-05:00,Dr. Reddy's Inks Deal to Sell Neurology Branded Products,"Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.",RDY,en,Zacks Investment Research
2019-06-10 16:30:00-05:00,Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug,Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.,RDY,en,Zacks Investment Research
2019-06-03 21:45:14-05:00,"Stocks in the news: GE Power, LTTS, ICICI Bank, Wipro, Axis Bank and Dr Reddy's Labs",HSBC maintained a 'buy' rating on Finolex Industries and revised target price to ₹680.,RDY,en,The Economic Times India
2019-05-20 14:06:00-05:00,"Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates",Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.,RDY,en,Zacks Investment Research
2019-05-20 07:48:43-05:00,Sell-siders cut Dr. Reddy's after FQ4 report; shares down 5% premarket,No summary available.,RDY,en,Seeking Alpha
2019-05-20 05:44:24-05:00,Dr Reddy's to spend upto $ 300 million on R&D in FY 20,"Dr Reddy's Laboratories is planning to spend upto USD 300 million on research and development (R&D) during this financial year, a senior official of the company has said.President, CFO and global head (HR) of Dr Reddy's Saumen Chakraborty, during an 'earnings call', said the drug- maker spent USD 226 million during the last fiscal against USD 264 million in FY 18.The R&D spend for the quarter (January-March FY 19) is Rs 366 crore, that is USD 53 million and EBIT 9.19 per cent of the sales for the quarter, he said.The spend is lowered by 16 per cent year-on-year and is flat on a sequential quarter basis. The spend for FY 19 is Rs 1,551 crore. That is USD 226 million as against USD 264 million in FY 18, Chakraborty said.""We expect the overall R&D for FY 20 would be in the range of USD 250 million to USD 300 million,"" he said replying to a query.The company would continue to focus on R&D for some interesting pipeline of proprietary products. But, on an overall basis, the R&D spend would be lower in proprietary products when compared to previous year, he further said.",RDY,en,The Economic Times India
2019-05-20 05:20:04-05:00,Dr Reddys Laboratories to spend upto $300 million on RD in FY20,The company would continue to focus on RD for some interesting pipeline of proprietary products.,RDY,en,Moneycontrol
2019-05-17 16:10:10-05:00,Dr. Reddy's Laboratories Ltd (RDY) CEO Gunupati Prasad on Q4 2019 Results - Earnings Call Transcript,No summary available.,RDY,en,Seeking Alpha
2019-05-17 06:32:00-05:00,"Dr. Reddy's (RDY) Earnings Rise In Q4, Revenues Beat",https://www.investing.com/analysis/dr-reddys-rdy-earnings-rise-in-q4-revenues-beat-200422437,RDY,en,Investing.com
2019-05-17 05:42:47-05:00,Dr. Reddy's beats Q4 consensus,No summary available.,RDY,en,Seeking Alpha
2019-05-17 05:34:40-05:00,"Dr. Reddy's beats by $0.05, beats on revenue",No summary available.,RDY,en,Seeking Alpha
2019-05-17 05:03:36-05:00,Dr Reddy’s Q4 net up 44% YoY at Rs 434cr,"Revenue rose 14 percent YoY to Rs 4,016.6 crore.",RDY,en,Moneycontrol
2019-05-16 22:57:51-05:00,Dr Reddy's Q4 preview: Profit to rise 37% YoY to Rs 413cr; EBITDA margin may touch 23%,Narnolia Financial Advisors expects the pharma company to report a net profit of Rs 545 crore as against Rs 500 crore in the last quarter,RDY,en,Moneycontrol
2019-05-16 22:30:34-05:00,Rupee opens lower at 70.26 per dollar,"Today, USD-INR pair is expected to quote in the range of 70.05 and 70.70, says Motilal Oswal.",RDY,en,Moneycontrol
2019-05-16 21:54:44-05:00,Options Trade | An Iron Condor trade in Dr Reddy's Laboratories,An Iron Condor trade in Dr Reddys Laboratories ahead of its results to benefit from high implied volatiltiy,RDY,en,Moneycontrol
2019-05-16 21:54:44-05:00,Options Trade | An Iron Condor trade in Dr Reddy#39;s Laboratories,An Iron Condor trade in Dr Reddys Laboratories ahead of its results to benefit from high implied volatiltiy,RDY,en,Moneycontrol
2019-05-16 21:54:20-05:00,VIEWPOINT | 5 small changes for big savings!,"Being a shopaholic might help you feel good but it impacts your monthly savings. Going for shopping with a list is an old-school idea, which still works in helping you avoid frivolous expenses.",RDY,en,Moneycontrol
2019-05-16 21:53:29-05:00,Explainer | Wealth creation: Why you must focus on investing as much as possible for the longer term,"The longer you let your money work hard, the more money you take home. If you keep investing your monthly commitment, you will walk away with a large sum.",RDY,en,Moneycontrol
2019-05-15 20:46:27-05:00,Ex-FDA chief Scott Gottlieb endorses use of generic drugs,"MUMBAI: The US generic drug industry, dominated by Indian companies, has found a surprising champion in former US Food and Drug Administration head Scott Gottlieb. He’s come out in support of generic drugs, which have been facing negative publicity over quality issues.Gottlieb, 46, who resigned in the middle of his tenure in March this year, has been tweeting to convince patients that generic drugs are safe, a move that should boost the image of several manufacturers, including Indian pharma companies that have been criticised in the past for poor quality standards.“I take generic drugs and have extreme confidence in them. I prescribed them to help my patients achieve value in their healthcare,” he tweeted on May 13. “Some bad problems arose years ago. We learned from them; and responded. Today’s generic drug framework is vigilant and upholds FDA’s gold standard.” Nearly 90% of medicines that American patients take are non-branded generics. Across the world, they have become one of the key means of providing accessible healthcare, being cheaper than branded drugs.Increased Oversight“I wouldn’t say Gottlieb is taking our side.",RDY,en,The Economic Times India
2019-05-15 05:48:44-05:00,Dr. Reddy's launches Daptomycin for Injection in U.S.,No summary available.,RDY,en,Seeking Alpha
2019-05-14 16:03:20-05:00,Saving Capitalism: Some Modest Proposals,No summary available.,RDY,en,Seeking Alpha
2019-05-14 00:12:56-05:00,7 Indian pharma cos face multiple US lawsuits,"MUMBAI: More than 40 US states filed lawsuits against pharma majors, including seven domestic companies, over collusion in inflating prices of widely prescribed generic medicines, in certain cases as high as 1,000%. The 500-page case filed by US states on May 10 charged global biggies like Teva, Pfizer, Sandoz and Mylan, as well as domestic companies like Sun Pharma’s US arm Taro, Zydus, Lupin, Aurobindo, Dr Reddy’s, Wockhardt and Glenmark with conspiring to inflate prices of medicines, and stifling competition for generic drugs.The lawsuit widens a complaint of price collusion filed in 2016, which is still pending in US courts after being first investigated in 2014. Domestic companies said they would defend these allegations. A Sun Pharma spokesperson said, “We believe the allegations made in these lawsuits are without merit, and we will continue to vigorously defend against them.”The US probe on price-fixing seems to have impacted the domestic pharma sector overall, with stock prices of most companies witnessing a drop on the BSE in the range of 4-9% on Monday.",RDY,en,The Economic Times India
2019-05-13 06:13:43-05:00,Pharma stocks bleed as US states file lawsuit against generic drug firms,"Lupin, Aurobindo Pharma, Dr Reddy’s, Glenmark, Wockhardt USA and Zydus have been named in the lawsuit.",RDY,en,The Economic Times India
2019-05-08 01:45:04-05:00,"D-St Buzz: Over 150 stocks hit new 52-week low on NSE; RIL, Zee Ent fall 2-5% each","The top Nifty gainers include UPL, JSW Steel, BPCL, Indian Oil Corporation and Power Grid while BPCL, Zee Entertainment, Vedanta, Reliance Industries, Bajaj Finserv and Dr Reddy's Labs are the top losers.",RDY,en,Moneycontrol
2019-05-06 04:49:45-05:00,"Dr. Reddy's Lab launches Testosterone Gel, 1.62% in U.S.",No summary available.,RDY,en,Seeking Alpha
2019-05-06 02:22:05-05:00,Dr Reddy's Laboratories launches generic testosterone gel in US market,The company's testosterone gel 1.62 percent is a therapeutic equivalent generic version of AndroGel 1.62 percent of AbbVie Inc.,RDY,en,Moneycontrol
2019-05-03 06:49:09-05:00,"The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Alcon AG (NYSE: ALC ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 2) EXACT Sciences Corporation (NASDAQ: EXAS ) KemPharm Inc (NASDAQ: KMPH ) NeoGenomics, Inc. (NASDAQ: NEO ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) Strongbridge Biopharma plc (NASDAQ: SBBP ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Verastem Inc (NASDAQ: VSTM ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) (reported negative trial results ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Stock In Focus Obseva Reports Positive Results For Long-Term Study Of Endometriosis Drug Obseva SA (NASDAQ: OBSV ) reported follow-up results from the Phase 2b EDELWEISS clinical trial of its oral gonadotropin-releasing hormone receptor antagonist linzagolix for treating endometriosis-related pelvic pain, showing that patients treating with linzagolix for 52 weeks saw maintenance of pelvic pain response rates, with the 75mg or the 200mg dose.",RDY,en,Benzinga
2019-04-26 11:53:34-05:00,Lilly prevails in Alimta patent appeal,No summary available.,RDY,en,Seeking Alpha
2019-04-26 03:02:21-05:00,D-Street Buzz: Nifty Auto underperforms dragged by Tata Motors; Aurobindo Pharma at 4-month high,"The top Nifty gainers include Tata Steel, BPCL, Axis Bank, Cipla and GAIL India while Tata Motors, Maruti Suzuki, Grasim Industries, Dr Reddy's Labs and Bharti Airtel are the top losers.",RDY,en,Moneycontrol
2019-04-25 22:30:59-05:00,Rupee opens higher at 70.09 per dollar,"Today, USD-INR pair is expected to quote in the range of 70.05-69.80 and 70.60-70.80, says Motilal Oswal.",RDY,en,Moneycontrol
2019-04-23 11:26:30-05:00,First exec indicted over role in opioid crisis,No summary available.,RDY,en,Seeking Alpha
2019-04-21 20:40:27-05:00,Carlyle-Zydus and Advent join race to acquire Bharat Serums and Vaccines Ltd,"MUMBAI: A consortium of Carlyle and Zydus Cadila is competing with private equity group Advent International to acquire Mumbaibased bio-pharmaceutical company Bharat Serums and Vaccines Ltd. (BSV). The two have submitted non-binding offers in the range of Rs 3,450-3,600 crore ($500-520 million), said multiple sources aware of the matter.They are up against domestic pharma companies Dr Reddy's Labs, Chrys Capital-backed Mankind Pharma and Goldman Sachs which have also made offers in the range of Rs 3,000 crore ($400-440 million), said one of the persons cited above.The binding offers are due this month end.However, the overall process has been slow due to the valuation mismatch. The founder promoters, the Daftary family, is believed to expecting a valuation of $600-630 million (Rs 4,000-4,300 crore) for their company. The Daftary family, existing investors Kotak Private Equity and Orbimed Asia are looking to sell a majority stake in the company and had mandated investment bank Jefferies to manage the sale process, ET had first reported in August last year.The two funds together hold 23% stake and the rest is with the founders.",RDY,en,The Economic Times India
2019-04-18 22:22:01-05:00,New legal risks emerge for Indian pharma,"Dr Reddy’s Labs, Aurobindo, Cadila and Glenmark face the highest risk",RDY,en,The Economic Times India
2019-04-17 04:45:43-05:00,Dr Reddy’s Laboratories Q4 PAT seen up 36.9% YoY to Rs. 413.6 cr: Kotak,"Net Sales are expected to increase by 7.7 percent Y-o-Y (down 1.1 percent Q-o-Q) to Rs. 3,807.5 crore, according to Kotak.",RDY,en,Moneycontrol
2019-04-16 12:31:32-05:00,Lannett down 4% on cautious SA article on alleged price collusion,No summary available.,RDY,en,Seeking Alpha
2019-04-16 00:54:52-05:00,Dr Reddy’s Laboratories gains on EIR from USFDA,"The share touched its 52-week high Rs 2,875 and 52-week low Rs 1,888 on 04 February, 2019 and 21 May, 2018, respectively.",RDY,en,Moneycontrol
2019-04-16 00:54:09-05:00,Podcast | NSE Invest O Cast episode 21: How your risk appetite shapes your portfolio,"For today’s podcast, we have got a risk expert who is going to tell you how your risk appetite shapes your portfolio.",RDY,en,Moneycontrol
2019-04-15 06:08:00-05:00,Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs,Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.,RDY,en,Zacks Investment Research
2019-04-15 05:41:09-05:00,Dr. Reddy's Lab acquires ANDA portfolio,"Dr. Reddy’s Laboratories (RDY) to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications ((ANDAs)) in U.S. The portfolio includ",RDY,en,Seeking Alpha
2019-04-15 02:19:57-05:00,"D-Street Buzz: Nifty Metal outshines led by Tata Steel; TCS jumps 3%, Infosys top loser","The top Nifty gainers include Tata Motors, Coal India, Tata Steel, TCS and Hindalco Industries while Infosys, Indian Oil Corporation, Sun Pharma, BPCL and Dr Reddy's Labs.",RDY,en,Moneycontrol
2019-04-15 01:45:49-05:00,Dr Reddy's falls despite ANDA portfolio acquisition in US; Nomura sees 22% upside,Japanese brokerage house Nomura said the deal is positive both from a strategic as well as a financial perspective.,RDY,en,Moneycontrol
2019-04-14 21:08:42-05:00,"Stocks in the news: TCS, Infosys, Dr Reddy's, Metropolis, Suven Life, Jet Airways, APL Apollo",Metropolis Healthcare | Suven Life | Jet Airways | Mcleod Russel | Dr Reddy's Labs and APL Apollo Tubes are stocks which are in the news today.,RDY,en,Moneycontrol
2019-04-12 02:30:25-05:00,Dr. Reddy’s Laboratories Q4 PAT seen up 88.4% YoY to Rs. 512.7 cr: Prabhudas Lilladher,"Net Sales are expected to increase by 12.4 percent Y-o-Y (up 3.4 percent Q-o-Q) to Rs. 3,994.3 crore, according to Prabhudas Lilladher.",RDY,en,Moneycontrol
2019-04-10 21:31:28-05:00,Indian pharma firms named in massive price-fixing scam in US,"Connecticut, which is leading a multistate investigation of an anti-trust lawsuit against 18 generic pharma companies, including five Indian firms, over price cartelisation on Wednesday said it has unsealed some key details of possibly the “largest cartel case in the history of the United States”.Initials and titles of individuals implicated in the conspiracy, industry “code words” and previously undisclosed emails from drug companies “brazenly discussing strategy to violate federal and state antitrust laws” have been uncovered, the Office of Attorney General of Connecticut that filed this suit in said.The Indian generic makers named in the lawsuit are Aurobindo, Dr Reddy’s, Emcure, Glenmark, and Zydus. The other generic makers named in the suit include Apotex, Teva, Heritage Pharma, and Par Pharma, The state of Connecticut alleged that these drug companies entered into conspiracies to fix prices and allocate customers in order to inflate and manipulate prices, reduce competition, and unreasonably restrain trade for 15 separate generic drugs.",RDY,en,The Economic Times India
2019-04-03 07:19:01-05:00,"The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY )(announced a settlement agreement with Celgene Corporation (NASDAQ: CELG ) regarding its ANDA related to generic Revlimid pending before Health Canada) Down In The Dumps (Biotech stocks hitting 52-week lows on April 2) Evoke Pharma Inc (NASDAQ: EVOK )(FDA issued a complete response letter for Gimoti, which is being evaluated for treating symptoms in adult women with acute and recurrent diabetic gastroparesis. Stock In Focus Advaxis To Offer Common Stock Advaxis, Inc. (NASDAQ: ADXS ), which rallied sharply Monday in reaction to clinical trial updates, announced its intention to offer its common stock in an underwritten public offering. The company said it intends to use the net proceeds to fund its R&D initiatives and for general corporate purposes. The stock slid 15.59 percent to $4.98 in after-hours trading.",RDY,en,Benzinga
2019-04-02 01:11:05-05:00,Dr Reddy's Laboratories settles case with US-based Celgene related to cancer drug,REVLIMID (Lenalidomide) is indicated for treatment for multiple myeloma (cancer).,RDY,en,Moneycontrol
2019-04-02 01:04:42-05:00,Dr Reddy's sells specialty derma brands in US to Encore Dermatology,"Sernivo Spray, Promiseb topical Cream and Trainex are the brands sold to US-based Encore Dermatology.",RDY,en,Moneycontrol
2019-04-02 00:53:18-05:00,Cyient Limited nosedives 11% after $5 million delivery order gets delayed,"At 1038 hrs, Cyient Limited was quoting Rs 578, down 11.02 percent on the BSE.",RDY,en,Moneycontrol
2019-04-02 00:53:05-05:00,"BJP, Congress locked in tight battle in Arunachal Pradesh assembly seat",The state is going to simultaneous Lok Sabha and assembly polls on April 11.,RDY,en,Moneycontrol
2019-04-02 00:52:05-05:00,SC declines urgent hearing on Hardik Patel's plea,The matter was mentioned for urgent listing before a bench headed by Justice Arun Mishra.,RDY,en,Moneycontrol
2019-04-02 00:49:05-05:00,Gorkhaland not a poll issue in Darjeeling for first time in over three decades,"Senior TMC leader and minister Gautam Deb feels that the statehood demand has caused a lot of bloodshed in the Hills, while development has taken a backseat.",RDY,en,Moneycontrol
2019-04-02 00:46:01-05:00,"Most power, bank & sugar stocks gain following SC judgment on RBI Feb 12 circular","RattanIndia Power was quoting at Rs 2.96, up Rs 0.25, or 9.23 percent.",RDY,en,Moneycontrol
2019-04-02 00:44:05-05:00,Lok Sabha polls 2019: Congress fields Mohan Joshi against BJP's Girish Bapat in Pune,"Lok Sabha elections to 48 seats in Maharashtra will be held in four phases on April 11, 18, 23 and 29 and the results will be declared on May 23.",RDY,en,Moneycontrol
2019-03-28 15:55:32-05:00,FDA's Gottlieb proposes higher standard for future opioid approvals,No summary available.,RDY,en,Seeking Alpha
2019-03-28 00:44:52-05:00,Dr Reddy’s declines as Credit Suisse maintains 'underperform',"The company is planning to launch more than 20 products in the US in FY20 and aiming to grow 2-3% higher than market growth rate in India, says Credit Suisse.",RDY,en,Moneycontrol
2019-03-28 00:42:03-05:00,RCom falls 5 percent after lenders invoke promoters' pledged shares,"At 1101 hrs, RCom was quoting Rs 4.35, down 4.81 percent on the BSE.",RDY,en,Moneycontrol
2019-03-28 00:39:32-05:00,Slideshow | These 8 brokerage picks could give 7-60% return over 9-15 months,Here are the top eight chart picks that could return 7-60 percent in next 9-15 months,RDY,en,Moneycontrol
2019-03-28 00:38:42-05:00,Lloyds Metals and Energy gains 6% after Maha govt confers 'mega project' status,"At 1036 hrs, Lloyds Metals and Energy was quoting Rs 12.62, up 5.87 percent on the BSE.",RDY,en,Moneycontrol
2019-03-28 00:37:41-05:00,Lok Sabha polls: Sarabjit Singh’s sister in contention for BJP ticket from Sirsa,Haryana's Sirsa seat has never been won by the BJP.,RDY,en,Moneycontrol
2019-03-28 00:30:50-05:00,Ruby Mills adds 3% even after labour unrest halts production,"At 1016 hrs, Ruby Mills was quoting Rs 279, up 3.09 percent on the BSE.",RDY,en,Moneycontrol
2019-03-28 00:29:19-05:00,"No home, no vote: Disgruntled homebuyers plan to exercise the NOTA option in Lok Sabha polls",Some buyers say that NOTA may not be the best option and is merely a namesake tool. Buyers will still end up voting for the wrong candidate. They should rather fight for the Right to Recall a candidate if he does not meet their expectations,RDY,en,Moneycontrol
2019-03-28 00:29:19-05:00,"No home, no vote: Disgruntled homebuyers plan to exercise NOTA option in Lok Sabha polls",Some buyers say that NOTA may not be the best option and is merely a namesake tool. Buyers will still end up voting for the wrong candidate. They should rather fight for the Right to Recall a candidate if he does not meet their expectations,RDY,en,Moneycontrol
2019-03-26 11:39:24-05:00,Purdue Pharma settles opioid case in OK for $270M,No summary available.,RDY,en,Seeking Alpha
2019-03-24 21:58:36-05:00,"Stocks in the news: TechM, Mindtree, Dr Reddy's Labs, Rel Infra, Finolex Cables and Tata Motors",Lead banker SBI may ask a retired senior banker to head Jet Airways.,RDY,en,The Economic Times India
2019-03-21 06:51:16-05:00,"The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 20) AstraZeneca plc (NYSE: AZN ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) Cytokinetics, Inc. (NASDAQ: CYTK )(Following planned interim analysis, the company along with partner Amgen, Inc. (NASDAQ: AMGN ) (announced a large-scale Phase 3 study evaluating their cardiac myosin activator omecamtiv mecarbil in 8000 heart failure patients will continue unchanged.) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Glaukos Corp (NYSE: GKOS ) Millendo Therapeutics Inc (NASDAQ: MLND ) Orthopediatrics Corp (NASDAQ: KIDS ) Qiagen NV (NYSE: QGEN ) Veracyte Inc (NASDAQ: VCYT ) XBiotech Inc (NASDAQ: XBIT ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 20) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evogene Ltd (NASDAQ: EVGN ) G1 Therapeutics Inc (NASDAQ: GTHX ) resTORbio, Inc. (NASDAQ: TORC ) (priced its common stock offering …",RDY,en,Benzinga
2019-03-20 05:19:51-05:00,"D-Street Buzz: Nifty Energy in red dragged by HPCL, BPCL; SpiceJet jumps 9%, RIL most active","The top Nifty gainers included Indiabulls Housing Finance, Infosys, Wipro, Hindalco Industries and Dr Reddy's Labs while the top losers included Zee Entertainment, ONGC, HPCL, BPCL, and NTPC.",RDY,en,Moneycontrol
2019-03-11 13:05:07-05:00,FDA seeks $643M funding increase aimed at key initiatives,No summary available.,RDY,en,Seeking Alpha
2019-03-11 11:02:44-05:00,Canada to institute tighter restrictions on opioid marketing,No summary available.,RDY,en,Seeking Alpha
2019-03-04 13:14:42-05:00,Painkiller stocks in the red on possible Purdue bankruptcy,No summary available.,RDY,en,Seeking Alpha
2019-02-20 12:30:50-05:00,Dr. Reddy's relaunches generic Suboxone,No summary available.,RDY,en,Seeking Alpha
2019-02-19 13:37:18-05:00,Maryland strikes out in reviving drug price-gouging law,No summary available.,RDY,en,Seeking Alpha
2019-02-15 10:48:00-05:00,FDA creates new accelerated review pathway for generic drug applications,No summary available.,RDY,en,Seeking Alpha
2019-02-13 07:43:46-05:00,Teva's soft outlook pressures generic peers,No summary available.,RDY,en,Seeking Alpha
2019-02-12 07:23:13-05:00,Dr. Reddy's launches Tadalafil tablets in U.S.,No summary available.,RDY,en,Seeking Alpha
2019-02-11 12:33:53-05:00,Celgene prevails in Revlimid patent challenge from Dr. Reddy's,No summary available.,RDY,en,Seeking Alpha
2019-02-11 08:43:39-05:00,Dr. Reddy's down 6% premarket after FDA inspection,No summary available.,RDY,en,Seeking Alpha
2019-02-05 10:52:43-05:00,Indivior fails in appeal to reinstate injunction against generic competitor to Suboxone; shares down 5%,No summary available.,RDY,en,Seeking Alpha
2019-02-01 08:09:40-05:00,Dr. Reddy's +3% on Q3 results,No summary available.,RDY,en,Seeking Alpha
2019-02-01 06:43:04-05:00,Dr. Reddy's Laboratories Limited 2019 Q3 - Results - Earnings Call Slides,No summary available.,RDY,en,Seeking Alpha
2019-02-01 06:36:42-05:00,"Dr. Reddy's beats by $0.16, misses on revenue",No summary available.,RDY,en,Seeking Alpha
2019-01-28 05:56:38-05:00,FDA approves Dr. Reddy's TOSYMRA in U.S.,No summary available.,RDY,en,Seeking Alpha
2019-01-25 07:21:54-05:00,Non-profit to offer ~20 generic drugs to hospitals this year,No summary available.,RDY,en,Seeking Alpha
2019-01-24 06:18:13-05:00,Dr. Reddy's launches propofol injectable emulsion in U.S.,No summary available.,RDY,en,Seeking Alpha
2019-01-15 12:45:44-05:00,FDA Commish touts advances/successes,No summary available.,RDY,en,Seeking Alpha
2019-01-15 12:45:44-05:00,FDA Commish touts advances/successes,No summary available.,RDY,en,Seeking Alpha
2019-01-09 13:18:11-05:00,Dr. Reddy's Laboratories (RDY) To Present At 37th Annual J.P. Morgan Healthcare Conference - Slideshow,No summary available.,RDY,en,Seeking Alpha
